【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2218次   下载 2036 本文二维码信息
码上扫一扫!
津力达颗粒对糖尿病大鼠肾及心血管组织肾素-血管紧张素系统的影响
吴莹,史婧丽,宋玉萍,韩冲,梁翠,刘志民*
0
(第二军医大学长征医院内分泌科,上海 200003
*通信作者)
摘要:
目的 观察津力达颗粒(JLG)对实验性糖尿病大鼠肾脏、心脏和腹主动脉组织肾素-血管紧张素系统(RAS)的影响,探讨JLG保护糖尿病患者肾脏及心血管的可能机制。方法 采用随机数字表法将大鼠分为糖尿病模型组20只和正常对照组(CON组)10只。CON组喂以普通饲料;糖尿病模型组喂以高脂饲料,喂养4周后用30 mg/kg链脲佐菌素(STZ)腹腔注射诱导糖尿病模型。诱导糖尿病模型成功后,再随机分成糖尿病津力达治疗组[DM+JLG组:JLG 3 g/(kg·d)灌胃]和糖尿病未治疗组(DM组),每组10只。8周后取肾、心脏及腹主动脉,采用ELISA法测定各组织匀浆血管紧张素Ⅰ(AngⅠ)、血管紧张素Ⅱ(AngⅡ)水平,蛋白质印迹分析法检测血管紧张素Ⅱ1型受体(AT1R)、血管紧张素Ⅱ2型受体(AT2R)的表达。结果 与CON组相比,DM组大鼠双肾质量/体质量、心脏质量/体质量、血糖、24 h尿蛋白增加(P<0.05),体质量减少(P<0.05),肾脏、心室肌和腹主动脉组织AngⅠ、AngⅡ、AT1R、AT2R水平升高 (P<0.05)。与DM组相比,DM+JLG组大鼠双肾质量/体质量、血糖、24 h尿蛋白降低(P<0.05),体质量增加(P<0.05),肾脏、心室肌和腹主动脉组织AngⅠ、AngⅡ、AT1R、AT2R水平降低 (P<0.05)。结论 JLG能降低实验性糖尿病大鼠肾脏、心脏及腹主动脉组织血管紧张素及其受体水平,有利于保护肾脏及心血管系统。
关键词:  糖尿病;津力达颗粒;肾素-血管紧张素系统    心血管系统
DOI:10.3724/SP.J.1008.2012.001065
投稿时间:2012-01-13修订日期:2012-04-20
基金项目:国家重点基础研究发展计划(“973”计划,2005CB523304).
Effects of Jinlida granules on renin-angiotensin system in kidney and cardiovascular tissues of diabetic rats
WU Ying,SHI Jing-li,SONG Yu-ping,HAN Chong,LIANG Cui,LIU Zhi-min*
(Department of Endocrinology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
*Corresponding author.)
Abstract:
ObjectiveTo evaluate the effects of Jinlida granules on the renin-angiotensin system (RAS) in the kidney, heart and abdominal aorta of experimental diabetic rats, so as to explore the possible mechanism by which Jinlida granules protect the kidney and cardiovascular system. MethodsThe rats were randomized into 2 groups: normal contronl group (CON group, n=l0) and diabetic model group (n=20). Rats in the control group were fed with regular chow; those in the diabetic model group were fed with high-fat diet for 4 weeks, and then were administered with streptozotocin (STZ; 30 mg/kg) by intraperitoneal injection to induce diabetic model. Successful diabetic models were further randomized into two groups with 10 in each: Jinlida granules treatment group (DM + JLG group) and non-treatment group (DM group). Rats in DM+JLG group were given Jinlida granules orally (3 g/kg per day) for 8 weeks. AngiotensinⅠ(AngⅠ) and angiotensin Ⅱ(AngⅡ) were measured by enzyme-linked immunosorbent assay (ELISA) in the homogenates of the kidney, heart and abdominal aorta; the protein expression of angiotensin Ⅱ type 1 receptor (AT1R) and angiotensin Ⅱ type 2 receptor (AT2R) was detected by Western blotting analysis. ResultsCompared with CON group, the kidney mass/body mass(KM/BM), heart mass/body mass (HM/BM), blood glucose (BG), and 24-hour urine proteins (24 h UP) were significantly increased in the DM group (P<0.05), the BM was significantly decreased(P<0.05), and the expression of AngⅠ, AngⅡ, AT1R and AT2R in the kidney, heart and abdominal aorta were significantly increased (P<0.05). Compared with DM group, the KM/BM and 24 h UP in DM + JLG group were significantly decreased (P<0.05), the BM was significantly increased (P<0.05), and the expression of AngⅠ, AngⅡ, AT1R and AT2R in the kidney, heart and abdominal aorta were significantly decreased (P<0.05). ConclusionJinlida granules can decrease the levels of AngⅠ, AngⅡ, AT1R and AT2R in the kidney, heart and abdominal aorta of diabetic rats, which is beneficial for protecting the kidney and cardiovascular system.
Key words:  diabetes mellitus  Jinlida granules  renin-angiotensin system  kidney  cardiovascular system